Bionorica compensates sales of the cannabis division

DGAP-Media / 2020-03-06 / 13:31 
 
*Herbal drug manufacturer gains market shares in all countries* 
 
· Significant growth compared with competition 
 
· Clinical trial shows effect in the market 
 
· Bionorica fastest growing OTC company in Germany(1) and Russia(2) 
 
*Neumarkt i.d.OPf., Düsseldorf, 06/03/2020 - *With a strong dynamic edge 
compared to the competition, the Sinupret manufacturer Bionorica, market 
leader for scientifically researched herbal remedies, is expanding its 
position in Germany and other countries. At the annual press conference in 
Düsseldorf today, the group of companies announced a 7.3 percent increase in 
sales to EUR 333.5 million(3). Despite negative developments in various 
pharmaceutical markets, Bionorica's international sales actually increased 
by 10.75 percent to EUR 206 million. 
 
*Market shares of Bionorica preparations continue to rise* 
"With these results, Bionorica remains on track for success. In 2019, we 
compensated for the sales of the cannabis division with our core business 
and gained market shares in all countries", emphasizes Prof. Dr. Michael A. 
Popp, CEO and owner of Bionorica SE. Taking Germany as an example: Increased 
sales of Sinupret, Bronchipret, Imupret and Canephron have increased the 
market share in the phyto market to 16.4 percent(4). "In 2019, German 
pharmacies sold more than 11 million units of Sinupret alone, making it the 
best-selling herbal medicine in Germany(5). The development of all our 
preparations has made Bionorica the most dynamic and fastest growing company 
among the top 10 German OTC companies(6)", adds Dr. Uwe Baumann, Head of 
Global Business at Bionorica SE. 
 
*Herbal remedy on a par with an antibiotic* 
One of the factors contributing to this growth was the internationally 
published clinical trial on Canephron, which has received much attention 
from physicians and pharmacists. The study proves that the herbal remedy is 
not inferior to an antibiotic in the treatment of acute uncomplicated 
urinary tract infections(7). Bionorica is thus contributing to the reduction 
of antibiotic prescriptions. Against this background, Canephron saw a 
significant year-on-year increase in pharmacy sell-out sales in units in 
2019 in Germany as well as in Russia, Poland and Austria(8). The company 
also hopes that the recent inclusion of Sinupret extract in the official 
treatment guideline "European Position Paper on Rhinosinusitis and Nasal 
Polyps" (EPOS) of the European and international professional ENT 
associations(9) will generate further market impetus. 
 
*Research to be further expanded* 
Bionorica plans to build on these research successes. "We want to bring new 
medicinal products to market maturity in the foreseeable future, including 
in the fields of metabolic syndrome, liver health and urology", said Prof. 
Popp. For this reason, the globally unique natural substance research centre 
Phytovalley(R) in the Tyrolean capital of Innsbruck will be further 
strengthened. In addition to existing in-house research facilities and 
cooperations, the Bavarian entrepreneur founded the "Michael Popp Research 
Institute for new Phyto Entities" together with the State of Tyrol, which 
opened in January 2020. The focus is on new therapeutic approaches for 
inflammation, metabolic disorders and cancer. 
 
*Equity ratio and number of employees on the rise again* 
Bionorica is financially well positioned for this ambitious research 
programme. The equity ratio(10), which rose to 83.8 percent in 2019, will 
ensure further organic growth independent of banks. In 2020, the herbal 
remedy maker plans to invest almost EUR 50 million. A new office building is 
currently being constructed at the company headquarters in Neumarkt, which 
will provide space for an additional 200 employees. As a result of the 3.4 
percent increase in the number of employees in 2019, the company employed 
1,822 people worldwide at the end of 2019, with more than half of them in 
Germany(11). New additions include 70 employees in Turkey with an own site 
in Istanbul. Three Bionorica preparations are already available in Turkish 
pharmacies, and further products will be introduced gradually.Market entry 
in France and Spain is planned for next year. 
 
*Sources:* 
 
(1) Insight Health ApoFusion, Pharmacy sell-out sales in Euro at retail 
price level, "OTC market": Pharmaceuticals, phyto-pharmaceuticals, 
dietetics, homeopathy, medical devices, food supplements and anthroposophy 
(2) IQVIA, Russia: best companies in absolute sales growth, MAT 06/19 
(3) Finance, SAP, sales 2019 adjusted for the Bionorica cannabis division 
sold in 2019; preliminary sales, auditor's certificate pending (sales 2019: 
EUR 333.5 million / 2018: EUR 310.7 million = growth of 7.3%) 
(4) Insight Health ApoFusion, pharmacy sell-out sales in units, 
"phyto-market": All OTC phyto-pharmaceuticals, Bionorica phyto-portfolio: 
excluding Rinupret, Mastodynon and Tonsipret 
(5) Insight Health ApoFusion, Sinupret pharmacy sell-out sales in units 
(6) Insight Health ApoFusion, pharmacy sell-out sales in euros at retail 
price level, MAT 12/2019 vs. MAT 12/2018 and MAT 12/2019 vs. MAT 12/2017, 
"OTC market": Pharmaceuticals, phyto-pharmaceuticals, dietetics, homeopathy, 
medical devices, food supplements and anthroposophy 
(7) CanUTI-7 study https://www.karger.com/Article/FullText/493368 [1] 
(8) Canephron pharmacy sell-out sales in units: Germany +14.8% (Insight 
Health Apo Fusion), Poland +97.5% (Pharma Sequence), Austria +70.1% (Iqvia), 
Russia +39.4% (DSM) 
(9) "European Position Paper on Rhinosinusitis and Nasal Polyps" (EPOS) 
2020, in Rhinology, Vol.58, supplement 29, Feb 2020, Official Journal of the 
European and International Rhinology Societies and of the Confederation of 
European ORL-HNS 
(10) Financial statement of Bionorica SE, equity ratio 2019: 83.8% and 2018: 
74.7% 
(11) Number of employees as of the reporting date 31/12/2019 
 
*Company profile* 
Patients want effective and tolerable medications and so herbal remedies are 
the preferred option. Bionorica, located in Neumarkt in Bavaria's Oberpfalz 
region, is the world's leading manufacturer of scientifically researched 
herbal remedies. Physicians, pharmacists and patients in more than 40 
countries trust in our effective products with few side effects. In 2019, 
the Bionorica Group achieved sales of EUR 333,5 million*. The company's 
equity ratio is almost 84 percent. Over 1,800 employees at 20 Bionorica 
locations worldwide work every day to carry on this success story, which 
began in Nuremberg 87 years ago. 
Based on its "Phytoneering" strategy, Bionorica decodes the extensive active 
ingredient potential of plants (phytos) using state-of-the-art research and 
technology (engineering). The result: highly effective medicines with few 
side effects. Our research and development priorities involve the treatment 
of symptoms in the respiratory tract, urinary tract, women's health and the 
immune system. 
*preliminary sales figures for the Bionorica Group, subject to confirmation 
by auditors 
 
*Press contact* 
Bionorica SE 
Lion Pfeufer 
Head of Media and Public Relations 
Kerschensteinerstraße 11-15 
92318 Neumarkt, Germany 
Phone [phone] 
Telefax +49 (0)9181/231-67423 
Email: [e-mail] 
http://english.bionorica.de/en/service/press-media.html [2] 
 
End of Media Release 
Additional features: 
 
Picture: http://newsfeed2.eqs.com/bionorica/989535.html [3] 
Subtitle: Dr. Uwe Baumann und Prof. Dr. Michael A. Popp bei der 
Bilanzpressekonferenz der Bionorica SE am 4. März 2020 in Neumarkt 
 
Issuer: Bionorica SE 
Key word(s): Health 
 
2020-03-06 Dissemination of a Press Release, transmitted by DGAP - a service 
of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
 
The DGAP Distribution Services include Regulatory Announcements, 
Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
989535 2020-03-06 
 
 
1: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=a2bc44e9ba1d7fc7ad9537b161416554&application_id=989535&site_id=vwd&application_name=news 
2: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=206075a977ded722cb1ef0f0a9ce8c45&application_id=989535&site_id=vwd&application_name=news 
3: https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=redirect&url=942252769bbddc872e06fbc644d95aa7&application_id=989535&site_id=vwd&application_name=news 
 

(END) Dow Jones Newswires

March 06, 2020 07:31 ET (12:31 GMT)